Guggenheim raises Elevance stock price target on earnings growth outlook

Guggenheim raised its Elevance Health price target to $485 from $460 and maintained a Buy rating, citing stronger 2027 EPS estimates and positive operating trends. Elevance reported Q3 2026 adjusted diluted EPS of $6.99 versus $4.70 expected and revenue of $50.4 billion versus $49.32 billion, and raised its full-year outlook; shares nevertheless edged lower in pre-market trading. Guggenheim estimates 2026 health insurance exchange margins of 2%–3%, below the company’s mid-single-digit target, while projecting EPS growth above 12% over the next couple of years.

Analysis

The headline references Meta, but the supplied reporting is about Elevance; there is no grounded inference here for META. For ELV, the key issue is earnings quality, not the size of the reported beat: the article flags possible reliance on favorable non-operating items and says $0.25 of exchange-market favorability was incorporated into the earnings baseline. That makes the raised 2027 estimate more dependent on whether underlying medical-cost trends and exchange margins actually improve, rather than on one quarter’s headline EPS. Over the next 1–3 months, the read-through is claims experience and management’s evidence that Medicaid rate actions are catching up with costs; over 6–18 months, sustained exchange-margin recovery and Carelon execution would support the earnings-growth case. The bullish analyst revision may help sentiment, but proximity to the 52-week high leaves less room for disappointment. Key downside risks are adverse utilization, delayed or inadequate Medicaid rate adjustments, and exchange claims deterioration. The article does not provide enough detail to isolate the contribution of non-operating items or independently validate the margin trajectory; those are the facts to verify before underwriting a durable re-rating.

Key Decisions for Investors

• Do not trade META on this item: its headline and the supplied Elevance reporting are mismatched.
• For ELV, avoid chasing the earnings beat. Consider a measured long only after the next claims/utilization update supports improving medical-cost trends and exchange margins; treat this as a 1–3 month confirmation trade, not a clean estimate-revision signal.
• Track adjusted EPS reconciliation, especially the contribution of non-operating items and the treatment of the $0.25 exchange favorability in the baseline. If operating results fail to substantiate the raised outlook, the analyst-driven bullish case is vulnerable to reversal.
• Falsify the constructive ELV thesis if management cuts its outlook, exchange claims worsen, or Medicaid rate increases lag cost trends; sustained margin recovery and operating earnings growth would strengthen it.